Outpost Medicine

Advancing the frontier of drug development in urology and gynecology

Outpost Medicine is committed to developing novel therapeutics for the treatment of urologic and gynecologic diseases. The company has been granted an exclusive license by Takeda Pharmaceutical Company Limited for the worldwide development and commercialization rights to OP-233 (formerly TAK-233). OP-223 is a clinical-stage product candidate being studied for the treatment of stress urinary incontinence, a disorder which affects millions of patients with no approved pharmaceutical therapies.

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Boston, Massachusetts